Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 70Neoplasms 13Neoplasm Metastasis 7Brain Neoplasms 7Head and Neck Neoplasms 6Breast Neoplasms, Male 6Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Ovarian Neoplasms 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Salivary Gland Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Osteitis Deformans 2Neuroma, Acoustic 2Neurofibromatosis 2 2Inflammatory Breast Neoplasms 2Glioblastoma 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Ependymoma 2Colorectal Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Hepatocellular 2Bile Duct Neoplasms 2

Interventions

beta-Aminoethyl Isothiourea 1Trastuzumab 1Patient Navigation 1N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 1Lapatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Patient Compliance × Lapatinib × Clear all
NCT01273610 2025-06-10

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

City of Hope Medical Center

Phase 2 Active not recruiting
40 enrolled 15 charts
Breast

Breast Neoplasms, Patient Compliance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡